DB-1310 by Duality Biologics (Shanghai) for Solid Tumor: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DB-1310 overview

The therapeutic candidates are under development for the treatment of metastatic solid tumor, non-small cell lung cancer, castration resistant prostate cancer and head and neck squamous cell cancer and HER2 positive breast cancer. The drug candidate is administered through intravenous route as injection. They are antibody drug conjugates (ADCs) developing based on duality immune toxin antibody conjugate platform.

Duality Biologics (Shanghai) overview

Duality Biologics (Shanghai) is a company focusing on the development, commercialization and discovery of new modality biologics to provide solutions. The company is headquartered in Shanghai, China. 

For a complete picture of DB-1310’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.